Who we are learn more Our journey began in 2007 and we constantly grow in order to provide the highest quality services in the Molecular Medicine sector. A passionate team sharing the same vision on quality healthcare and molecular science is working together in order to provide patients and physicians with reliable actionable information. Our aim is to individualize the journey of patients from diagnosis to treatment selection and response and to reveal their genetic predisposition to Hereditary Syndromes. Our mission is to revolutionize the personalized treatment of patients by developing and offering highly sensitive and specific molecular assays that are applicable in everyday clinical practice, incorporating state-of-the-art technology and assisting physicians in applying cutting edge tools for individualized medicine worldwide The clinical expertise of Genekor focuses on: Response to Targeted Therapy Pharmacogenetics Determination of Hereditary Cancer, cardiovascular Diseases and Neurological Disorders New Unique Technological Platforms (OncotypeDX BreastTM, HerediGENETM, PrIMeTM, Cordis DXTM, Cerebrum DX TM, PCA3TM) The specialized laboratories of GeneKor Medical S.A. are accredited by the Hellenic Accreditation Systems S.A (ESYD) under the terms of the ELOT EN ISO 15189:2012 (Cert. No. 822) and Certified with ISO 9001:2015 (Cert. No. 041150049) and ELOT ISO/IEC 27001:2013 (Cert.No 048190009) by TUV NORD HELLAS. GeneKor is staffed by board certified internationally recognized and published scientists and doctors who are able to provide analysis and recommendations to physicians and their patients. Therefore, GeneKor is in position to carry out all existing molecular biology assays. GeneKor offers to the treating physicians of various specialties tools to individualize their patients’ treatment needs. At GeneKor, we are devoted at offering services of the highest quality, by constantly monitoring the scientific developments in the health sector, updating our laboratory equipment and maximizing our levels of accuracy and reliability. GeneKor is actively establishing its international presence with an ultimate goal to extend its collaborations in more countries. Our strategic goal is the constant incorporation of new technology platforms and assays in order to always provide the most up-to-date, reliable and cutting edge tools to the treating physicians. Certifications The Management and the Scientific Team of GeneKor Medical laboratories are focused on providing the highest quality of Molecular Services. The specialized laboratories of GeneKor Medical S.A. are accredited by the Hellenic Accreditation Systems S.A (ESYD) under the terms of the ELOT EN ISO 15189:2012 (Cert. No. 822). Certified with ELOT EN ISO 9001:2015 (Cert. No. 041150049) and ELOT ISO/IEC 27001:2013 (Cert.No 048190009) by TUV NORD HELLAS. Our services are assured by participating in proficiency testing (PT) programs by: CAP (College of American Pathologists). External Quality Assurance EMQN (European Molecular and Genetics Quality Network). UKNEQAS –ICC & ISH (United Kingdom National External Quality Assessment Services, Immunohistochemistry & In-situ Hybridization). GenQA (Genomics Quality Assessment). Genekor is certified by external quality assessment for the following tests: Mutation analysis in BRCA1 & BRCA2 genes (Breast Cancer susceptibility genes 1 and 2) – EMQN & CAP Somatic mutation analysis (EGFR, BRAF, KRAS, KIT, NRAS, HRAS & PDGFRA gene) – CAP, EMQN & GenQA Analysis of DNA Microsatellite Instability (MSI) - GenQA Detection and quantification of the ALK gene rearrangements – UKNEQAS (ICC&ISH) Detection and quantification of the overexpression of the HER2/neu gene - UKNEQAS (ICC&ISH) Certifications Files Please click on the Download button, in order to view the certifications of Genekor Medical S.A. Download General Meeting Invitation of the Shareholders of the Company under the title “GENEKOR PRIVATE DIAGNOSTIC LABORATORY MEDICAL SA” and the distinctive title “GENEKOR IAE” in the annual Regular General Meeting on the 14th of June 2018, Tuesday, at 16.00 p.m. at the Company's premises in Gerakas, Pallini, Attica (52 Spaton Ave). Invitation of the Shareholders of the Company under the title “GENEKOR PRIVATE DIAGNOSTIC LABORATORY MEDICAL SA” and the distinctive title “GENEKOR IAE” in the annual Regular General Meeting on the 10th of September 2020, Tuesday, at 16.00 p.m. at the Company's premises in Gerakas, Pallini, Attica (52 Spaton Ave). About Contact us © 2017 GENEKOR MEDICAL S.A. All rights reserved | Terms of Use | Secure Transactions | Sitemap Committed to biotechnological innovation Change cookies consent Revoke cookies consent